The global Adalimumab market size was valued at USD 150.2 million in 2023 and is forecast to a readjusted size of USD 201.8 million by 2030 with a CAGR of 4.3% during review period.
Adalimumab, sold under the trade name Humira among others, is a medication used to treat rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, chronic psoriasis, hidradenitis suppurativa, and juvenile idiopathic arthritis.
Adalimumab is a widely used biologic medication that belongs to the class of tumor necrosis factor (TNF) inhibitors. It is primarily prescribed for the treatment of autoimmune diseases such as rheumatoid arthritis, psoriasis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, and ulcerative colitis. Autoimmune diseases are on the rise globally, affecting millions of people. Adalimumab is one of the leading treatment options for these conditions, driving the demand for the medication. Improved awareness and diagnosis of autoimmune diseases have led to an increased demand for effective treatment options like adalimumab. Biologic drugs, including adalimumab, have gained popularity due to their targeted treatment approach and potential for better disease management. Patients are increasingly opting for these medications over conventional therapies, driving the market growth of adalimumab. Adalimumab has received approvals for an expanding range of indications, including pediatric use and additional inflammatory conditions. The availability of more indications and treatment options has expanded the addressable market for adalimumab. The expiration of adalimumab's patent in various regions has opened the doors for the entry of biosimilar versions of the drug. Biosimilars offer competitive pricing, increasing market accessibility and potentially driving the overall market growth. Reimbursement policies and insurance coverage play a significant role in the adoption and market drive of adalimumab. Favorable policies and coverage encourage patient access and contribute to the growth of the market. Advances in drug delivery systems, such as autoinjectors and pre-filled syringes, have increased the convenience and ease of administration for patients using adalimumab, enhancing its market drive.
This report includes an overview of the development of the Adalimumab industry chain, the market status of Adults (Adalimumab, Adalimumab Biosimilar), Children (Adalimumab, Adalimumab Biosimilar), and key enterprises in developed and developing market, and analysed the cutting-edge technology, patent, hot applications and market trends of Adalimumab.
Regionally, the report analyzes the Adalimumab markets in key regions. North America and Europe are experiencing steady growth, driven by government initiatives and increasing consumer awareness. Asia-Pacific, particularly China, leads the global Adalimumab market, with robust domestic demand, supportive policies, and a strong manufacturing base.
Key Features:
The report presents comprehensive understanding of the Adalimumab market. It provides a holistic view of the industry, as well as detailed insights into individual components and stakeholders. The report analysis market dynamics, trends, challenges, and opportunities within the Adalimumab industry.
The report involves analyzing the market at a macro level:
麻豆原创 Sizing and Segmentation: Report collect data on the overall market size, including the sales quantity (K Units), revenue generated, and market share of different by Type (e.g., Adalimumab, Adalimumab Biosimilar).
Industry Analysis: Report analyse the broader industry trends, such as government policies and regulations, technological advancements, consumer preferences, and market dynamics. This analysis helps in understanding the key drivers and challenges influencing the Adalimumab market.
Regional Analysis: The report involves examining the Adalimumab market at a regional or national level. Report analyses regional factors such as government incentives, infrastructure development, economic conditions, and consumer behaviour to identify variations and opportunities within different markets.
麻豆原创 Projections: Report covers the gathered data and analysis to make future projections and forecasts for the Adalimumab market. This may include estimating market growth rates, predicting market demand, and identifying emerging trends.
The report also involves a more granular approach to Adalimumab:
Company Analysis: Report covers individual Adalimumab manufacturers, suppliers, and other relevant industry players. This analysis includes studying their financial performance, market positioning, product portfolios, partnerships, and strategies.
Consumer Analysis: Report covers data on consumer behaviour, preferences, and attitudes towards Adalimumab This may involve surveys, interviews, and analysis of consumer reviews and feedback from different by Application (Adults, Children).
Technology Analysis: Report covers specific technologies relevant to Adalimumab. It assesses the current state, advancements, and potential future developments in Adalimumab areas.
Competitive Landscape: By analyzing individual companies, suppliers, and consumers, the report present insights into the competitive landscape of the Adalimumab market. This analysis helps understand market share, competitive advantages, and potential areas for differentiation among industry players.
麻豆原创 Validation: The report involves validating findings and projections through primary research, such as surveys, interviews, and focus groups.
麻豆原创 Segmentation
Adalimumab market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value.
麻豆原创 segment by Type
Adalimumab
Adalimumab Biosimilar
麻豆原创 segment by Application
Adults
Children
Major players covered
AbbVie
Amgen
Sandoz
Boehringer Ingelheim
Mylan
Biogen
Aark Pharmaceuticals
Amgevita
Delphis Pharma
麻豆原创 segment by region, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Adalimumab product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Adalimumab, with price, sales, revenue and global market share of Adalimumab from 2019 to 2024.
Chapter 3, the Adalimumab competitive situation, sales quantity, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Adalimumab breakdown data are shown at the regional level, to show the sales quantity, consumption value and growth by regions, from 2019 to 2030.
Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2019 to 2030.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value and market share for key countries in the world, from 2017 to 2023.and Adalimumab market forecast, by regions, type and application, with sales and revenue, from 2025 to 2030.
Chapter 12, market dynamics, drivers, restraints, trends and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Adalimumab.
Chapter 14 and 15, to describe Adalimumab sales channel, distributors, customers, research findings and conclusion.
Please Note - This is an on demand report and will be delivered in 2 business days (48 Hours) post payment.
1 麻豆原创 Overview
1.1 Product Overview and Scope of Adalimumab
1.2 麻豆原创 Estimation Caveats and Base Year
1.3 麻豆原创 Analysis by Type
1.3.1 Overview: Global Adalimumab Consumption Value by Type: 2019 Versus 2023 Versus 2030
1.3.2 Adalimumab
1.3.3 Adalimumab Biosimilar
1.4 麻豆原创 Analysis by Application
1.4.1 Overview: Global Adalimumab Consumption Value by Application: 2019 Versus 2023 Versus 2030
1.4.2 Adults
1.4.3 Children
1.5 Global Adalimumab 麻豆原创 Size & Forecast
1.5.1 Global Adalimumab Consumption Value (2019 & 2023 & 2030)
1.5.2 Global Adalimumab Sales Quantity (2019-2030)
1.5.3 Global Adalimumab Average Price (2019-2030)
2 Manufacturers Profiles
2.1 AbbVie
2.1.1 AbbVie Details
2.1.2 AbbVie Major Business
2.1.3 AbbVie Adalimumab Product and Services
2.1.4 AbbVie Adalimumab Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.1.5 AbbVie Recent Developments/Updates
2.2 Amgen
2.2.1 Amgen Details
2.2.2 Amgen Major Business
2.2.3 Amgen Adalimumab Product and Services
2.2.4 Amgen Adalimumab Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.2.5 Amgen Recent Developments/Updates
2.3 Sandoz
2.3.1 Sandoz Details
2.3.2 Sandoz Major Business
2.3.3 Sandoz Adalimumab Product and Services
2.3.4 Sandoz Adalimumab Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.3.5 Sandoz Recent Developments/Updates
2.4 Boehringer Ingelheim
2.4.1 Boehringer Ingelheim Details
2.4.2 Boehringer Ingelheim Major Business
2.4.3 Boehringer Ingelheim Adalimumab Product and Services
2.4.4 Boehringer Ingelheim Adalimumab Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.4.5 Boehringer Ingelheim Recent Developments/Updates
2.5 Mylan
2.5.1 Mylan Details
2.5.2 Mylan Major Business
2.5.3 Mylan Adalimumab Product and Services
2.5.4 Mylan Adalimumab Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.5.5 Mylan Recent Developments/Updates
2.6 Biogen
2.6.1 Biogen Details
2.6.2 Biogen Major Business
2.6.3 Biogen Adalimumab Product and Services
2.6.4 Biogen Adalimumab Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.6.5 Biogen Recent Developments/Updates
2.7 Aark Pharmaceuticals
2.7.1 Aark Pharmaceuticals Details
2.7.2 Aark Pharmaceuticals Major Business
2.7.3 Aark Pharmaceuticals Adalimumab Product and Services
2.7.4 Aark Pharmaceuticals Adalimumab Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.7.5 Aark Pharmaceuticals Recent Developments/Updates
2.8 Amgevita
2.8.1 Amgevita Details
2.8.2 Amgevita Major Business
2.8.3 Amgevita Adalimumab Product and Services
2.8.4 Amgevita Adalimumab Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.8.5 Amgevita Recent Developments/Updates
2.9 Delphis Pharma
2.9.1 Delphis Pharma Details
2.9.2 Delphis Pharma Major Business
2.9.3 Delphis Pharma Adalimumab Product and Services
2.9.4 Delphis Pharma Adalimumab Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.9.5 Delphis Pharma Recent Developments/Updates
3 Competitive Environment: Adalimumab by Manufacturer
3.1 Global Adalimumab Sales Quantity by Manufacturer (2019-2024)
3.2 Global Adalimumab Revenue by Manufacturer (2019-2024)
3.3 Global Adalimumab Average Price by Manufacturer (2019-2024)
3.4 麻豆原创 Share Analysis (2023)
3.4.1 Producer Shipments of Adalimumab by Manufacturer Revenue ($MM) and 麻豆原创 Share (%): 2023
3.4.2 Top 3 Adalimumab Manufacturer 麻豆原创 Share in 2023
3.4.2 Top 6 Adalimumab Manufacturer 麻豆原创 Share in 2023
3.5 Adalimumab 麻豆原创: Overall Company Footprint Analysis
3.5.1 Adalimumab 麻豆原创: Region Footprint
3.5.2 Adalimumab 麻豆原创: Company Product Type Footprint
3.5.3 Adalimumab 麻豆原创: Company Product Application Footprint
3.6 New 麻豆原创 Entrants and Barriers to 麻豆原创 Entry
3.7 Mergers, Acquisition, Agreements, and Collaborations
4 Consumption Analysis by Region
4.1 Global Adalimumab 麻豆原创 Size by Region
4.1.1 Global Adalimumab Sales Quantity by Region (2019-2030)
4.1.2 Global Adalimumab Consumption Value by Region (2019-2030)
4.1.3 Global Adalimumab Average Price by Region (2019-2030)
4.2 North America Adalimumab Consumption Value (2019-2030)
4.3 Europe Adalimumab Consumption Value (2019-2030)
4.4 Asia-Pacific Adalimumab Consumption Value (2019-2030)
4.5 South America Adalimumab Consumption Value (2019-2030)
4.6 Middle East and Africa Adalimumab Consumption Value (2019-2030)
5 麻豆原创 Segment by Type
5.1 Global Adalimumab Sales Quantity by Type (2019-2030)
5.2 Global Adalimumab Consumption Value by Type (2019-2030)
5.3 Global Adalimumab Average Price by Type (2019-2030)
6 麻豆原创 Segment by Application
6.1 Global Adalimumab Sales Quantity by Application (2019-2030)
6.2 Global Adalimumab Consumption Value by Application (2019-2030)
6.3 Global Adalimumab Average Price by Application (2019-2030)
7 North America
7.1 North America Adalimumab Sales Quantity by Type (2019-2030)
7.2 North America Adalimumab Sales Quantity by Application (2019-2030)
7.3 North America Adalimumab 麻豆原创 Size by Country
7.3.1 North America Adalimumab Sales Quantity by Country (2019-2030)
7.3.2 North America Adalimumab Consumption Value by Country (2019-2030)
7.3.3 United States 麻豆原创 Size and Forecast (2019-2030)
7.3.4 Canada 麻豆原创 Size and Forecast (2019-2030)
7.3.5 Mexico 麻豆原创 Size and Forecast (2019-2030)
8 Europe
8.1 Europe Adalimumab Sales Quantity by Type (2019-2030)
8.2 Europe Adalimumab Sales Quantity by Application (2019-2030)
8.3 Europe Adalimumab 麻豆原创 Size by Country
8.3.1 Europe Adalimumab Sales Quantity by Country (2019-2030)
8.3.2 Europe Adalimumab Consumption Value by Country (2019-2030)
8.3.3 Germany 麻豆原创 Size and Forecast (2019-2030)
8.3.4 France 麻豆原创 Size and Forecast (2019-2030)
8.3.5 United Kingdom 麻豆原创 Size and Forecast (2019-2030)
8.3.6 Russia 麻豆原创 Size and Forecast (2019-2030)
8.3.7 Italy 麻豆原创 Size and Forecast (2019-2030)
9 Asia-Pacific
9.1 Asia-Pacific Adalimumab Sales Quantity by Type (2019-2030)
9.2 Asia-Pacific Adalimumab Sales Quantity by Application (2019-2030)
9.3 Asia-Pacific Adalimumab 麻豆原创 Size by Region
9.3.1 Asia-Pacific Adalimumab Sales Quantity by Region (2019-2030)
9.3.2 Asia-Pacific Adalimumab Consumption Value by Region (2019-2030)
9.3.3 China 麻豆原创 Size and Forecast (2019-2030)
9.3.4 Japan 麻豆原创 Size and Forecast (2019-2030)
9.3.5 Korea 麻豆原创 Size and Forecast (2019-2030)
9.3.6 India 麻豆原创 Size and Forecast (2019-2030)
9.3.7 Southeast Asia 麻豆原创 Size and Forecast (2019-2030)
9.3.8 Australia 麻豆原创 Size and Forecast (2019-2030)
10 South America
10.1 South America Adalimumab Sales Quantity by Type (2019-2030)
10.2 South America Adalimumab Sales Quantity by Application (2019-2030)
10.3 South America Adalimumab 麻豆原创 Size by Country
10.3.1 South America Adalimumab Sales Quantity by Country (2019-2030)
10.3.2 South America Adalimumab Consumption Value by Country (2019-2030)
10.3.3 Brazil 麻豆原创 Size and Forecast (2019-2030)
10.3.4 Argentina 麻豆原创 Size and Forecast (2019-2030)
11 Middle East & Africa
11.1 Middle East & Africa Adalimumab Sales Quantity by Type (2019-2030)
11.2 Middle East & Africa Adalimumab Sales Quantity by Application (2019-2030)
11.3 Middle East & Africa Adalimumab 麻豆原创 Size by Country
11.3.1 Middle East & Africa Adalimumab Sales Quantity by Country (2019-2030)
11.3.2 Middle East & Africa Adalimumab Consumption Value by Country (2019-2030)
11.3.3 Turkey 麻豆原创 Size and Forecast (2019-2030)
11.3.4 Egypt 麻豆原创 Size and Forecast (2019-2030)
11.3.5 Saudi Arabia 麻豆原创 Size and Forecast (2019-2030)
11.3.6 South Africa 麻豆原创 Size and Forecast (2019-2030)
12 麻豆原创 Dynamics
12.1 Adalimumab 麻豆原创 Drivers
12.2 Adalimumab 麻豆原创 Restraints
12.3 Adalimumab Trends Analysis
12.4 Porters Five Forces Analysis
12.4.1 Threat of New Entrants
12.4.2 Bargaining Power of Suppliers
12.4.3 Bargaining Power of Buyers
12.4.4 Threat of Substitutes
12.4.5 Competitive Rivalry
13 Raw Material and Industry Chain
13.1 Raw Material of Adalimumab and Key Manufacturers
13.2 Manufacturing Costs Percentage of Adalimumab
13.3 Adalimumab Production Process
13.4 Adalimumab Industrial Chain
14 Shipments by Distribution Channel
14.1 Sales Channel
14.1.1 Direct to End-User
14.1.2 Distributors
14.2 Adalimumab Typical Distributors
14.3 Adalimumab Typical Customers
15 Research Findings and Conclusion
16 Appendix
16.1 Methodology
16.2 Research Process and Data Source
16.3 Disclaimer
AbbVie
Amgen
Sandoz
Boehringer Ingelheim
Mylan
Biogen
Aark Pharmaceuticals
Amgevita
Delphis Pharma
听
听
*If Applicable.
